Video
Dr. Eric Klein on the “impressive” performance of IsoPSA in recent study
Author(s):
“I think the take home message is that [IsoPSA is] an easy test to use,” says Eric A. Klein, MD.
Video Player is loading.
In this video, Eric A. Klein, MD, discusses the key takeaways of the recent Urology Practice study “IsoPSA reduces provider recommendations for biopsy and magnetic resonance imaging in men with total prostate specific antigen ≥4 ng/mL: a real-world observational clinical utility study” and also shares what research is coming for the test. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
Related Videos
Ekene Enemchukwu, MD, on underutilization of vaginal estrogen for GSM
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Naeem Bhojani, MD, expands on key findings from WATER III trial
Hailey Frye discusses improvement of pain management for nephrolithiasis
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Related Content
